NIH awards Arrevus STTR grant for UTI research, CEO to speak at IMAP 2018

RALEIGH, N.C., June 12, 2018 /PRNewswire/ -- Arrevus Inc. (www.arrevus.com), a biotechnology company developing solutions to treat infections in immune-compromised patients, received a $300,000 STTR grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH), for research on multi-drug resistant bacterial (MDR) urinary tract infections (UTI).  UTIs create a significant burden on the healthcare system due in part to:

• Most common hospital-acquired infection
• UTI complications can result in kidney damage and sepsis
• High morbidity and mortality among cases with MDR bacterial pathogens

About ARV-1502

Arrevus is exploiting a unique approach to the prevention and management of bacterial drug resistance utilizing the Insect Derived Anti-Infectives (IDEA) platform of which ARV-1502 is the lead compound. The IDEA platform leverages millions of years of natural selection to identify and isolate fast acting, effective immune responses from insects-related peptides. ARV-1502 is an engineered peptide derived from these insect templates and is active against the most challenging pathogens, gram-negative antibiotic resistant bacteria, using a novel mechanism of action.

CEO Carl N. Kraus, M.D., to speak at IMAP 2018, Edinburgh, UK

The 8^th International Meeting on Antimicrobial Peptides (IMAP), a satellite conference of the 35^th European Peptide Symposium, will host a variety of international experts on the subject of Antimicrobial Peptides (AMP) and Host Defense Peptides (HDP). Specialized topics include:

• Synthesis and mode of action
• Role of AMPs and HDPs in fertility and reproduction
• Susceptibility testing of AMPs

IMAP takes place from September 2^nd – 4^th in Edinburgh, UK.

About Arrevus
Arrevus is applying evolutionary templates to develop first-in-class proprietary anti-infectives known as Designer Proline-rich Antimicrobial Peptide Chaperone Protein Inhibitors (DPCs).  Arrevus is headquartered in Raleigh, NC. For more information about Arrevus Inc., visit www.arrevus.com or email [email protected].

SOURCE Arrevus

Related Links

http://www.arrevus.com